Awamedica Announces Bioequivalence Studies at the AWABETIC Endocrine-Cardiorenal Forum Series

Awamedica announced the successful completion of bioequivalence studies for three pharmaceutical products during the AWABETIC Endocrine-Cardiorenal Forum series held in Duhok and Sulaymaniyah. The forums brought together healthcare professionals to discuss current developments in endocrine, cardiovascular, and renal care while highlighting evidence supporting locally manufactured medicines.

Phase IV studies, also known as post-marketing surveillance, evaluate the long-term safety and effectiveness of medicines after regulatory approval. These studies contribute to ongoing benefit–risk assessment in real-world clinical settings.

Drug recalls are structured regulatory actions taken to address quality, safety, or labeling concerns associated with medicinal products. Clear procedures and defined responsibilities ensure patient protection and supply chain integrity.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation management. Appropriate patient selection and risk assessment are essential to minimize gastrointestinal and cardiovascular complications.